2023
DOI: 10.1245/s10434-023-13722-x
|View full text |Cite
|
Sign up to set email alerts
|

Ultra-Low Dose of Superparamagnetic Iron Oxide Nanoparticles for Sentinel Lymph Node Detection in Patients with Breast Cancer

Abstract: Background Sentinel lymph node (SLN) status is pivotal for treatment decision-making in patients with breast cancer. Superparamagnetic iron oxide nanoparticles (SPIO) have been shown to be equivalent to the dual technique with technetium99m (Tc99) and blue dye (BD) for SLN detection. The aim of this study was to determine the feasibility of detecting SLNs using an ultra-low dose of SPIO. Method Patients planned for breast conserving surgery and SLN biopsy … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 21 publications
0
1
0
Order By: Relevance
“…However, magnetic residue was found to last in tissue up to at least 42 months postoperatively, causing artefacts on MRI scans in 40% of cases [17]. Further work has been carried out on SPIO magnetic tracers, including use of an ultra-low dose of 0.1 mL SPIO injections (compared to the usual 1-2 mL dose), achieving a 100% SLN detection rate with reduced skin staining [19]. However, further studies are needed to prove the long-term efficacy of this ultra-low dose, with follow-up imaging to prove a reduction in artefacts on MRI scans.…”
Section: Computed Tomography Lymphography (Ctlg)mentioning
confidence: 99%
“…However, magnetic residue was found to last in tissue up to at least 42 months postoperatively, causing artefacts on MRI scans in 40% of cases [17]. Further work has been carried out on SPIO magnetic tracers, including use of an ultra-low dose of 0.1 mL SPIO injections (compared to the usual 1-2 mL dose), achieving a 100% SLN detection rate with reduced skin staining [19]. However, further studies are needed to prove the long-term efficacy of this ultra-low dose, with follow-up imaging to prove a reduction in artefacts on MRI scans.…”
Section: Computed Tomography Lymphography (Ctlg)mentioning
confidence: 99%